Company Profile
Progyny Stock Price, News & Analysis
Company overview
Business overview
Progyny is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Progyny is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Progyny follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Progyny sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
PGNY is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Progyny's catalysts are fertility-benefit renewals, member growth, and deeper utilization across its women’s health platform. The company needs to show that its employer relationships keep turning into repeatable revenue.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
Progyny, Inc. Announces First Quarter 2026 Results
Source: Progyny
- 03
Progyny, Inc. Announces Third Quarter 2025 Results
Source: Progyny
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.